Hetairos is a histology-based artificial intelligence model for predicting central nervous system tumor methylation subtypes - Scorecard - MDSpire

Hetairos is a histology-based artificial intelligence model for predicting central nervous system tumor methylation subtypes

  • By

  • Darui Jin

  • Artem Shmatko

  • Areeba Patel

  • Samuel Rutz

  • Lukas Friedrich

  • Rouzbeh Banan

  • Ramin Rahmanzade

  • Philipp Sievers

  • Stefan Hamelmann

  • Daniel Schrimpf

  • Kirsten Göbel

  • Henri Bogumil

  • Sybren L. N. Maas

  • Martin Sill

  • Felix E. Hinz

  • Abigail K. Suwala

  • Felix Keller

  • Antje Habel

  • Gleb Rukhovich

  • Ferdinand Zettl

  • Obada T. Alhalabi

  • Sebastian Ille

  • Jannik Sehring

  • Daniel Amsel

  • Benedikt Wiestler

  • Pedro Piovesan Lago

  • Bogdana Suchorska

  • Olfat Ahmad

  • Dominik Sturm

  • David Reuss

  • Pieter Wesseling

  • Adelheid Wöhrer

  • Frank L. Heppner

  • Ingmar Blümcke

  • Claire Delbridge

  • Martin Jakobs

  • Christel Herold-Mende

  • Sandro M. Krieg

  • Wolfgang Wick

  • David T. W. Jones

  • Stefan M. Pfister

  • Maysa Al-Hussaini

  • Yanghao Hou

  • Felipe D’Almeida Costa

  • Leonille Schweizer

  • Luca Bertero

  • Till Acker

  • Arnault Tauziede-Espariat

  • Pascale Varlet

  • Doron Merkler

  • Kristof Egervari

  • Hildegard Dohmen

  • Pablo Zoroquiain

  • Roger Gejman

  • Sebastian Brandner

  • Xiangzhi Bai

  • Andreas von Deimling

  • Felix Sahm

  • Moritz Gerstung

  • June 10, 2026

  • 0 min

Share

Clinical Scorecard: Hetairos: An AI Model Utilizing Histological Data to Predict Methylation Subtypes in Central Nervous System Tumors

At a Glance

CategoryDetail
Condition
Key MechanismsMethylation profiling and AI-based classification of histological data (ensure direct sourcing).
Target Population
Care Setting

Key Highlights

  • Remove unsupported claims about accuracy and performance.

Guideline-Based Recommendations

Diagnosis

    Management

    • E
    • n
    • s
    • u
    • r
    • e
    • r
    • e
    • c
    • o
    • m
    • m
    • e
    • n
    • d
    • a
    • t
    • i
    • o
    • n
    • s
    • a
    • r
    • e
    • d
    • i
    • r
    • e
    • c
    • t
    • l
    • y
    • s
    • o
    • u
    • r
    • c
    • e
    • d
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Patients with various CNS tumor subtypes

        AI model provides faster diagnostic capabilities.

        Clinical Best Practices

        • Remove editorial interpretations; ensure practices are directly supported.

        Related Resources & Content

        Original Source(s)

        Hetairos is a histology-based artificial intelligence model for predicting central nervous system tumor methylation subtypes

        • by Darui Jin, Artem Shmatko, Areeba Patel, Samuel Rutz, Lukas Friedrich, Rouzbeh Banan, Ramin Rahmanzade, Philipp Sievers, Stefan Hamelmann, Daniel Schrimpf, Kirsten Göbel, Henri Bogumil, Sybren L. N. Maas, Martin Sill, Felix E. Hinz, Abigail K. Suwala, Felix Keller, Antje Habel, Gleb Rukhovich, Ferdinand Zettl, Obada T. Alhalabi, Sebastian Ille, Jannik Sehring, Daniel Amsel, Benedikt Wiestler, Pedro Piovesan Lago, Bogdana Suchorska, Olfat Ahmad, Dominik Sturm, David Reuss, Pieter Wesseling, Adelheid Wöhrer, Frank L. Heppner, Ingmar Blümcke, Claire Delbridge, Martin Jakobs, Christel Herold-Mende, Sandro M. Krieg, Wolfgang Wick, David T. W. Jones, Stefan M. Pfister, Maysa Al-Hussaini, Yanghao Hou, Felipe D’Almeida Costa, Leonille Schweizer, Luca Bertero, Till Acker, Arnault Tauziede-Espariat, Pascale Varlet, Doron Merkler, Kristof Egervari, Hildegard Dohmen, Pablo Zoroquiain, Roger Gejman, Sebastian Brandner, Xiangzhi Bai, Andreas von Deimling, Felix Sahm, Moritz Gerstung

        • June 10, 2026

        Related Content

        Neural regulation of tumor progression: implications for hepatocellular carcinoma

        Past present and future of radiosensitization in cervical cancer

        Temporal dynamics and determinants of early recurrence after curative resection for stage I-III rectal cancer: integrated analyses of hazard function, survival, and competing risks